16 September 2026 editorial review · Item
Hydroxychloroquine for stage-1 T1D prevention: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Preventing and curing evidence review — 16 September 2026
- Disposition: reviewed; no confirmed content change. Current item
lastReviewed: 2026-08-27. - Claim check: TN22 HR 0.95/futility and no reported retinal safety concern supported by trial publication; no prevention benefit.
- Registry NCT03428945: TERMINATED; updated 2024-04-09; enrollment 273 (ACTUAL); primary completion 2022-10-27 (ACTUAL); results posted.
- Primary publication/regulatory sources checked or consulted: dc23-1096.